Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 250, Issue 4, 2012, Pages 603-610

  Higashide, Tomomi ^a   Murotani, Eiji ^a   Saito, Yoshiaki ^a   Ohkubo, Shinji ^a   Sugiyama, Kazuhisa ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Adverse event; Bevacizumab; Central retinal artery occlusion; Neovascular glaucoma; Ocular ischemic syndrome

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AGED; ANTERIOR EYE SEGMENT; ARTICLE; CENTRAL RETINA ARTERY OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CEREBROVASCULAR ACCIDENT; DIABETIC RETINOPATHY; DRUG ADMINISTRATION ROUTE; ENDOPHTHALMITIS; FEMALE; HEART INFARCTION; HUMAN; INJECTION SITE INFLAMMATION; INJECTION SITE REACTION; LENS DISEASE; MAJOR CLINICAL STUDY; MALE; NEOVASCULAR GLAUCOMA; NEOVASCULARIZATION (PATHOLOGY); OCULAR ISCHEMIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; RADIATION INJURY; RETINA DETACHMENT; RETROSPECTIVE STUDY; VITREOUS HEMORRHAGE; CAROTID ARTERY OBSTRUCTION; CASE REPORT; DRUG ANTAGONISM; DRUG EFFECT; FLUORESCENCE ANGIOGRAPHY; INTERNAL CAROTID ARTERY; INTRAOCULAR DRUG ADMINISTRATION; INTRAOCULAR PRESSURE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; RETINA ARTERY OCCLUSION; VASCULARIZATION; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTERIOR EYE SEGMENT; ANTIBODIES, MONOCLONAL, HUMANIZED; CAROTID ARTERY, INTERNAL; CAROTID STENOSIS; FEMALE; FLUORESCEIN ANGIOGRAPHY; GLAUCOMA, NEOVASCULAR; HUMANS; INJECTIONS, INTRAOCULAR; INTRAOCULAR PRESSURE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RETINAL ARTERY OCCLUSION; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84861309670     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-011-1865-8     Document Type: Article

References (27)

1. Avery RL (2006) Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26:352-354
2. Gheith ME, Siam GA, de Barros DS, Garg SJ, Moster MR (2007) Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther 23:487-491
3. Chalam KV, Gupta SK, Grover S, Brar VS, Agarwal S (2008) Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma. Eur J Ophthalmol 18:255-262
4. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, Otori Y, Kamei M, Kusaka S, Tano Y (2008) Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 115:1571-1580, 1580.e1-3
5. Ehlers JP, Spirn MJ, Lam A, Sivalingam A, Samuel MA, Tasman W (2008) Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina 28:696-702
6. Gupta V, Jha R, Rao A, Kong G, Sihota R (2009) The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma. Eur J Ophthalmol 19:435-441
7. Saito Y, Higashide T, Takeda H, Ohkubo S, Sugiyama K (2010) Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma. Acta Ophthalmol 88:96-102
8. Moraczewski AL, Lee RK, Palmberg PF, Rosenfeld PJ, Feuer WJ (2009) Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab. Br J Ophthalmol 93:589-593
9. Saito Y, Higashide T, Takeda H, Murotani E, Ohkubo S, Sugiyama K (2010) Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab. Am J Ophthalmol 149:964.e1-972.e1
10. Fung AE, Rosenfeld PJ, Reichel E (2006) The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90:1344-1349
11. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ, Pan American Collaborative Retina Group (PACORES) (2008) Twelvemonth safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246:81-87
12. Shima C, Sakaguchi H, Gomi F, Kamei M, Ikuno Y, Oshima Y, Sawa M, Tsujikawa M, Kusaka S, Tano Y (2008) Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol Scand 86:372-376
13. Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP (1998) Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology 105:232-237
14. Matsuyama K, Ogata N, Jo N, Shima C, Matsuoka M, Matsumura M (2009) Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab. Jpn J Ophthalmol 53:243-248
15. Lim TH, Bae SH, Cho YJ, Lee JH, Kim HK, Sohn YH (2009) Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma. Korean J Ophthalmol 23:188-192
16. Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU, T̈bingen Bevacizumab Study Group, SchraermeyerU (2007) Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 143:995-1002
17. Mete A, Saygili O, Mete A, Bayram M, Bekir N (2010) Effects of intravitreal bevacizumab (Avastin) therapy on retrobulbar blood flow parameters in patients with neovascular age-related macular degeneration. J Clin Ultrasound 38:66-70
18. Bonnin P, Pournaras JA, Lazrak Z, Cohen SY, Legargasson JF,Gaudric A, Levy BI, Massin P (2010) Ultrasound assessment of short-term ocular vascular effects of intravitreal injection of bevacizumab (Avastin(®) ) in neovascular age-related macular degeneration. Acta Ophthalmol 88:641-645
19. Toklu Y, Cakmak HB, Raza S, Anayol A, Asik E, Sim?ek S (2011) Short-term effects of intravitreal bevacizumab (Avastin(®)) on retrobulbar hemodynamics in patients with neovascular agerelated macular degeneration. Acta Ophthalmol 89:e41-e45
20. Sacu S, Pemp B, Weigert G, Matt G, Garhofer G, Pruente C, Schmetterer L, Schmidt-Erfurth U (2011) Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion. Invest Ophthalmol Vis Sci 52:3046-3050
21. Kofoed PK, Munch IC, Larsen M (2010) Profound retinal ischaemia after ranibizumab administration in an eye with ocular ischaemic syndrome. Acta Ophthalmol 88:808-810
22. von Hanno T, Kinge B, Fossen K (2010) Retinal artery occlusion following intravitreal anti-VEGF therapy. Acta Ophthalmol 88:263-266
23. Mansour AM, Bynoe LA, Welch JC, Pesavento R, Mahendradas P, Ziemssen F, Pai SA (2010) Retinal vascular events after intravitreal bevacizumab. Acta Ophthalmol 88:730-735
24. Yokoyama K, Choshi T, Kimoto K, Shinoda K, Nakatsuka K (2008) Retinal circulatory disturbances following intracameral injection of bevacizumab for neovascular glaucoma. Acta Ophthalmol 86:927-928
25. Huang ZL, Lin KH, Lee YC, Sheu MM, Tsai RK (2010) Acute vision loss after intravitreal injection of bevacizumab (avastin) associated with ocular ischemic syndrome. Ophthalmologica 224:86-89
26. Amselem L, Montero J, Diaz-Llopis M, Pulido JS, Bakri SJ, Palomares P, Garcia-Delpech S (2007) Intravitreal bevacizumab (Avastin) injection in ocular ischemic syndrome. Am J Ophthalmol 144:122-124
27. Lee SJ, Lee JJ, Kim SY, Kim SD (2009) Intravitreal bevacizumab (Avastin) treatment of neovascular glaucoma in ocular ischemic syndrome. Korean J Ophthalmol 23:132-134